Approvals· Brief · October 15, 2026, 10:03 AM ET

EMA recommends authorisation of Rasonque for metastatic pancreatic cancer

EMA's CHMP has recommended granting a marketing authorisation for Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior treatment. The recommendation follows a phased review that shortened assessment to less than 150 days, with Rasonque showing a median overall survival of 12.4 months versus 6.7 months for chemotherapy in a phase 3 study of 500 patients.

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation